Brief: Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology

Zelluna ASA

11/05/2021 16:37

May 11 (Reuters) - Ultimovacs ASA  ULTIMO.OL :
    * ULTIMOVACS PUBLISHES POSITIVE LONG-TERM UV1 DATA FROM
PHASE I
MALIGNANT
    * ULTIMOVACS - PUBLISHES POSITIVE LONG-TERM UV1 DATA FROM
PHASE I
MALIGNANT MELANOMA COMBINATION STUDY IN FRONTIERS IN IMMUNOLOGY
    * ULTIMOVACS - ACHIEVEMENT OF THE PRIMARY ENDPOINTS OF
SAFETY AND
TOLERABILITY
    * ULTIMOVACS - 50% OF THE PATIENTS WERE STILL ALIVE AT THE
DATA
CUT-OFF
    * ULTIMOVACS - DATA SUPPORTS COMBINATION OF UV1 VACCINE WITH
IPILIMUMAB, A CTLA-4 CHECKPOINT INHIBITOR AND STANDARD-OF-CARE
TREATMENT
    * ULTIMOVACS - CURRENTLY ENROLLING INITIUM, PHASE II
CLINICAL
TRIAL EVALUATING UV1 IN COMBINATION WITH IPILIMUMAB, NIVOLUMAB
    * ULTIMOVACS - EXPECTS TO ANNOUNCE DATA ON PHASE II TRIAL'S
PRIMARY ENDPOINT IN 2H2022

Source text for Eikon:  ID:nObiXCRsga 
Further company coverage:  ULTIMO.OL 

 ((Reuters.Briefs@thomsonreuters.com;))